Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2007

01-06-2007 | Letter to the Editor

High Affinity of Ecabet Sodium for Inflamed Colonic Mucosa in Ulcerative Colitis

Authors: Keiichi Mitsuyama, Nobuo Tomiyasu, Junya Masuda, Hiroshi Yamasaki, Osamu Tsuruta, Michio Sata

Published in: Digestive Diseases and Sciences | Issue 6/2007

Login to get access

Excerpt

To the Editor: The pathogenesis of ulcerative colitis (UC) is unknown, but may be associated with inability of the colonic mucosa to protect itself from luminal challenges and/or with inappropriate effective repair following colonic injury. Therapeutic approaches aiming to promote the repair of the injured mucosa have included the use of mucosal protectants. Ecabet sodium, purified from pine resin, has been used widely in Japan as a nonabsorbable protectant in treating gastric ulcer [1]. Recently, benefit from ecabet sodium given by enema has been reported in treatment of UC [2] as well as in experimental colitis [3]. In the stomach, ecabet sodium has been found to adhere selectively to ulcerated gastric mucosa, showing a high affinity for injured gastric epithelium. In gastric ulcer, this agent promotes mucosal integrity, possibly by enhancing epithelial restitution, facilitating mucus synthesis and secretion, inducing prostaglandin production, and increasing mucosal blood flow [4, 5]. In intestinal epithelial cells in vitro, ecabet sodium activated extracellular signal-regulated kinases 1 and 2, and also induced cyclooxygenase-2 [6]. However, whether ecabet sodium adheres preferentially to inflamed colon as it does to ulcerated stomach remains unclear. We, therefore, evaluated the affinity of ecabet sodium for colonic mucosa in patients with UC. …
Literature
1.
go back to reference Onoda Y, Magaribuchi T, Tamaki H (1990) Effects of new anti-ulcer agent 12-sulfodehydroabietic acid monosodium salt on duodenal alkaline secretion in rats. Arzneimittelforschung 40:576–578PubMed Onoda Y, Magaribuchi T, Tamaki H (1990) Effects of new anti-ulcer agent 12-sulfodehydroabietic acid monosodium salt on duodenal alkaline secretion in rats. Arzneimittelforschung 40:576–578PubMed
2.
go back to reference Kono T, Nomura M, Kasai S, Kohgo Y (2001) Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study. Am J Gastroenterol 96:793–797PubMedCrossRef Kono T, Nomura M, Kasai S, Kohgo Y (2001) Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study. Am J Gastroenterol 96:793–797PubMedCrossRef
3.
go back to reference Noto T, Yamada H, Inui T, Okuyama K, Watanable A, Kimura I, Nagasaki M (2005) Therapeutic effects of ecabet sodium, an antiulcer drug, on dextran sodium sulfate-induced ulcerative colitis in rats. Dig Dis Sci 50:922–927PubMedCrossRef Noto T, Yamada H, Inui T, Okuyama K, Watanable A, Kimura I, Nagasaki M (2005) Therapeutic effects of ecabet sodium, an antiulcer drug, on dextran sodium sulfate-induced ulcerative colitis in rats. Dig Dis Sci 50:922–927PubMedCrossRef
4.
go back to reference Kinoshita M, Iwasaki H, Yaoshima A, Tamaki H (1993) Effects of ecabet sodium (TA-2711), a new antiulcer agent, on gastro-intestinal mucosal prostanoid production and morphology in rats. Biol Pharm Bull 18:850–853 Kinoshita M, Iwasaki H, Yaoshima A, Tamaki H (1993) Effects of ecabet sodium (TA-2711), a new antiulcer agent, on gastro-intestinal mucosal prostanoid production and morphology in rats. Biol Pharm Bull 18:850–853
5.
go back to reference Wada H, Kodato S, Kawamori M, Morikawa T, Nakai H, Takeda M, Saito S, Onoda Y, Tamaki H (1985) Antiulcer activity of dehydroabietic acid derivatives. Chem Pharm Bull 33:1472–1487PubMed Wada H, Kodato S, Kawamori M, Morikawa T, Nakai H, Takeda M, Saito S, Onoda Y, Tamaki H (1985) Antiulcer activity of dehydroabietic acid derivatives. Chem Pharm Bull 33:1472–1487PubMed
6.
go back to reference Sasaki K, Iizuka M, Konno S, Shindo K, Sato A, Horie Y, Watanabe S (2005) Ecabet sodium prevents the delay of wound repair in intestinal epithelial cells induced by hydrogen peroxide. J Gastroenterol 40:474–482PubMedCrossRef Sasaki K, Iizuka M, Konno S, Shindo K, Sato A, Horie Y, Watanabe S (2005) Ecabet sodium prevents the delay of wound repair in intestinal epithelial cells induced by hydrogen peroxide. J Gastroenterol 40:474–482PubMedCrossRef
7.
go back to reference Truelove SC, Witts LJ (1955) Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 2:1041–1048 Truelove SC, Witts LJ (1955) Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 2:1041–1048
Metadata
Title
High Affinity of Ecabet Sodium for Inflamed Colonic Mucosa in Ulcerative Colitis
Authors
Keiichi Mitsuyama
Nobuo Tomiyasu
Junya Masuda
Hiroshi Yamasaki
Osamu Tsuruta
Michio Sata
Publication date
01-06-2007
Published in
Digestive Diseases and Sciences / Issue 6/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9587-1

Other articles of this Issue 6/2007

Digestive Diseases and Sciences 6/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine